Janus kinase inhibitors in dermatology: Part I. A comprehensive review
Recommended Citation
Chapman S, Kwa M, Gold LS, and Lim HW. Janus kinase inhibitors in dermatology: Part I. A comprehensive review. J Am Acad Dermatol 2021.
Document Type
Article
Publication Date
7-8-2021
Publication Title
Journal of the American Academy of Dermatology
Abstract
The Janus kinase-signal transducer and activator of transcription (JAK-STAT) intracellular signaling pathway is utilized by many proinflammatory molecules to mediate downstream effects and activate gene transcription. Activation of the JAK-STAT pathway contributes to a number of inflammatory dermatoses. Clinical trials and smaller studies have demonstrated the efficacy of JAK inhibitors in the treatment of a variety of dermatologic conditions. Here, we review the use of JAK inhibitors for the treatment of a wide range of dermatologic diseases in a two-part review series.
PubMed ID
34246698
ePublication
ePub ahead of print
